Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study
Francesco Passamonti, Francesca Palandri, Güray Saydam, Jeannie Callum, Timothy Devos, Paola Guglielmelli, Alessandro M. Vannucchi, Evren Zor, Mike W. Zuurman, Geralyn Gilotti, Yifan Zhang, Martin Grießhammer
Topics & Concepts
RuxolitinibMedicinePolycythaemiaClinical endpointInternal medicinePhlebotomyMyelofibrosisPolycythemia veraClinical trialRandomized controlled trialPediatricsSurgeryBone marrowMyeloproliferative Neoplasms: Diagnosis and TreatmentSystemic Sclerosis and Related DiseasesIntracerebral and Subarachnoid Hemorrhage Research